The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

BACKGROUND: Rates of disease recurrence and death following surgery remain high in early-stage non-small-cell lung cancer (NSCLC), despite adjuvant treatment and curative intent. Recently, osimertinib showed overwhelming evidence for disease-free survival (DFS), as demonstrated by an overall reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardenberg, M.C., Patel, B., Matthews, C., Califano, R., Garcia Campelo, R., Grohe, C., Hong, M.H., Liu, G., Lu, S., de Marinis, F., Pérol, M., Soo, R.A., Stiles, B.M., Tiseo, M., Tsuboi, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588882/
https://www.ncbi.nlm.nih.gov/pubmed/36108559
http://dx.doi.org/10.1016/j.esmoop.2022.100572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588882/
https://www.ncbi.nlm.nih.gov/pubmed/36108559
http://dx.doi.org/10.1016/j.esmoop.2022.100572

Ejemplares similares